FSCM
LAB icon

Front Street Capital Management’s Standard BioTools LAB Stock Holding History

Front Street Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-141,231
Closed -$130K – 71
2026
Q1 		$130K Buy
141,231
+12,706
+10% +$15.4K 0.02% 72
2025
Q4 		$165K Sell
128,525
-24,706
-16% -$33.2K 0.02% 71
2025
Q3 		$199K Buy
153,231
+32,706
+27% +$42.8K 0.03% 72
2025
Q2 		$145K Buy
+120,525
New +$134K 0.03% 67

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Front Street Capital Management's LAB Position: Q2 2026 in Review

Front Street Capital Management sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 141,231 shares — an estimated $130K sold.

Front Street Capital Management first reported a position in LAB in Q2 2025 and held it in 4 quarters. The position peaked at $199K in Q3 2025. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Front Street Capital Management reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • Front Street Capital Management sold 141,231 Standard BioTools shares in Q2 2026, an estimated $130K.
  • Front Street Capital Management first reported a position in Standard BioTools in Q2 2025 and held it in 4 quarters.
  • Front Street Capital Management's Standard BioTools position peaked at $199K in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Front Street Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.